Issues with the assay of factor VIII activity in plasma and factor VIII concentrates

Thrombosis and Haemostasis

Volumn 84, Issue 6, 2000, Pages 942-948

  Lundblad, R L ^a   Kingdon, H S ^a   Mann, K G ^a   White, G C ^a  

^a NONE   (United States)

Author keywords

Chromogenic assays; Factor VIII; Factor VIII assay concentrates

Indexed keywords

BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR 8A; BLOOD CLOTTING FACTOR 9A; CALCIUM ION; CHROMOGENIC SUBSTRATE; PHOSPHOLIPID; RECOMBINANT BLOOD CLOTTING FACTOR 8; THROMBIN; VON WILLEBRAND FACTOR;

ASSAY; BLOOD CLOTTING; DIAGNOSTIC ACCURACY; DISEASE SEVERITY; DRUG ACTIVATION; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENCY; DRUG PURITY; HEMOPHILIA A; HUMAN; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; REVIEW;

EID: 0034533788     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1614153     Document Type: Review

References (113)

1. Treatment of haemophilia a by continuous factor VIII infusion
2. Stability of factor VIII concentrates after reconstitution
3. Evaluation of recombinant factor VIII (Kogenate®) stability for continuous infusion using a minipump infusion device
4. A practical guide to the evaluation and treatment of hemophilia
5. Pharmaceutical services in the treatment of haemophilic patients
6. A biological standard for measurement of blood coagulation factor VIII activity
7. Nomenclature of quantities and units in thrombosis and haemostasis
8. Standards for factor VIII
9. Problems in the standardization of factor VIII Assays
10. Discrepancies in potency assessment of recombinant factor VIII concentrates
11. Effect of antihemophilic factor on one-stage clotting tests. A presumptive assay for hemophilia and a simple one-stage antihemophilic factor assay procedure
12. Methodology of the one-stage assay of factor VIII (VIII: C)
13. Assay Discrepancies with Highly Purified Factor VIII Concentrates
14. Quality Assurance in Production of Plasma Proteins
15. Potency of high purity factor VIII concentrates
16. The behavior of different factor VIII concentrates in a chromogenic factor X-activating system
17. Activated Coagulation Factors: In-Vivo and in-vivo Studies
18. Assay of Blood Coagulation Factor VIII
19. The factor VIII complex: Structure and function
20. Factor VIII structure and function Blood 1989
21. Blood coagulation factors V and VIII: Structure and functional similarities and their relationships to hemorrhagic and thrombotic Disorders
22. The Purification, Structure and Function of Factor VIII
23. Factor VIII Structure and Function
24. The life cycle of factor VIII in view of its structure and function
25. The importance of activation of antihemophilic globulin and proaccelerin by traces of thrombin in the generation of intrinsic prothrombinase activity
26. Further evidence that thrombin-activation of factor VIII is an essential step in intrinsic clotting
27. Activation of low molecular weight fragment of antihemophilic factor (factor VIII) by thrombin
28. Thrombin activation of factor VIII. A comparison of purified factor VIII and the low molecular weight factor VIII procoagulant
29. The role of phospholipid and factor VIIIa in the activation of bovine factor X
30. Activation of Human Prothrombin by Human Prothrombinase. Influence of factor Va on the reaction mechanism
31. Interaction of feedback control and product inhibition in the activation of factor X by factors IXa and VIII
32. The use of acetylated factor X to prevent feedback activation of factor VIII during factor X activation: A tool for kinetic studies
33. Isolation and characterization of different activated forms of factor VIII, the human antihaemophilic A factor
34. Subunit structure of thrombin-activated porcine factor VIII
35. Human factor VIIIa subunit structure. Reconstitution of factor VIIIa from the isolated A1/A3-C1-C2 dimer and A2 subunit
36. Factor VIII S373L: Mutation at P1' site confers thrombin cleavage resistance causing mild haemophilia A
37. Direct characterization of factor VIII in plasma: Detection of a mutation altering a thrombin cleavage site (arginine-372 → histidine
38. Proteolytic requirements for thrombin activation of antihemophilic factor (Factor VIII)
39. Differential proteolytic activation of factor VIII-von Willebrand factor complex by thrombin
40. Cleavage of factor VIII light chain is required for maximal generation of factor VIIIa activity
41. A comparison of phospholipid and platelets in the activation of factor VIII by thrombin and factor Xa and in the activation of factor X
42. Activation of porcine factor VIII:C by thrombin and factor Xa
43. Proteolytic interactions of factor IXa with human factor VIII and factor VIIIa
44. Is there a relatively procoagulant-inactive form of normal antihemophilic factor (Factor VIII)?
45. Unfractionated heparin inhibits thrombin-catalyzed amplification reactions of coagulation more efficiently than those catalyzed by Factor Xa
46. The inhibition of thrombin-dependent positive-feedback reactions is critical to the expression of the anticoagulant effect of heparin
47. Kinetics of activation of human factor VIII by thrombin
48. In situ-generated thrombin is the only enzyme that effectively activates factor VIII and factor V in thromboplastin-activated plasma
49. A model for the tissue factor pathway to thrombin. II. A mathematical simulation
50. Evaluation of the initiation phase of blood coagulation using ultrasensitive assays for serine proteases
51. Evaluation of factor VIII deficient plasmas
52. An effect of predilution on potency assays of factor VIII concentrates
53. An effect of predilution on VIII:C determination by the one-stage Assay
54. Recommendations for the assay of high-purity factor VIII concentrates
55. Validation of a procedure for potency assessing of a high purity factor VIII concentrate. Comparison of different factor VIII coagulant assays and effect of prediluent
56. MS. Purified human factor VIII procoagulant protein: Comparative hemostatic response after infusions into hemophilic and von Willebrand disease dogs
57. In vivo characterization of recombinant factor VIII in a canine model of hemophilia A (factor VIII deficiency)
58. Stability of porcine factor VIII
59. Production of factor VIII deficient plasma by immunodepletion using three monoclonal antibodies
60. Preparation of factor-VIII-deficient plasma with antibodies and its use for the assay of factor VIII
61. vWF Is a cofactor for thrombin-catalyzed cleavage of the factor VIII light chain
62. The association of factor VIII with vWF
63. Low-molecular weight factor VIII requires a cofactor for its procoagulant activity
64. Influence of High-Molecular Weight Factor VIII on the Measurement of Low-Molecular Weight Factor VIII Procoagulant in Different Assay Systems
65. The effect of vWF on activation of factor VIII by factor Xa
66. vWF as a regulator of intrinsic factor X activation
67. Thrombin-activated and factor Xa-activated human factor VIII: Differences in cofactor activity and decay rate
68. Characterization of vWF in factor VIII concentrates
69. Purification, Biochemistry, and Structure/Function Relationships of vWF
70. Regulatory Control, Standardization and Characterization of Clinical Concentrates
71. Ultracentrifugal analysis of factor VIII and von Willebrand Factor in therapeutic preparations
72. Activated factor VIII in therapeutic preparations: Analysis by ultracentrifugation
73. Laboratory Assays for Factor VIII
74. The assay of antihaemophilic globulin
75. Methodology of the two-stage assay of factor VIII (VIII:C)
76. Assay of factor VIII with a chromogenic substrate
77. Spectrophotometric method for the assay of human blood coagulation factor VIII
78. Traces of factor VIII in substrate plasma
79. Cofactor proteins in the assembly and expression of blood clotting enzyme complexes
80. The assay of coagulation factors using synthetic chromogenic substrates
81. Coamate® FVIII - A new kit for the accurate chromogenic determination of FVIII activity in plasma and concentrates on automated instruments or manually
82. A new chromogenic factor VIII-assay based on a system of human proteins
83. Pharmacokinetics in vivo comparison of using 1-stage and chromogenic substrate assays with two formulations of Hemofil®
84. In vivo recovery of factor VIII: A comparison of one-stage and two-stage assay methods
85. Factor VIII:C (FVIII:C) recovery and half-life after infusion of steam-treated high-purity factor VIII concentrate in severe hemophilia A. A comparison of one-stage assay, two-stage assay and a chromogenic substrate assay
86. Pharmacokinetics of two pasteurized factor VIII concentrates by different and multicenter assays of factor VIII activity
87. On the unreliability of one-stage factor VIII:C clotting assays after influsion of factor VIII concentrates
88. Standardization and Assay
89. Approaches to the measurement of the in vivo response to factor VIII concentrate infusion
90. Kinetic evaluation of four Factor VIII concentrates by model-independent methods
91. Pharmacokinetics of a new heat-treated concentrate of factor VIII estimated by model-independent methods
92. Use of recombinant antihemophilic factor in the treatment of two patients with classic hemophilia
93. Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of hemophilia A
94. The design and analysis of half-life and recovery studies for factor VIII and factor IX
95. Comparative evaluation of the pharmacokinetics of three monoclonal factor VIII concentrates
96. Treatment of hemophilia A with a highly purified factor VIII concentrate prepared by anti-FVIIIc immuno-affinity chromatography
97. Low recovery in vivo of highly purified factor VIII in patients with hemophilia
98. Pharmacokinetics of factor VIII in humans. Obtaining clinically relevant data from comparative studies
99. Pharmacokinetic properties of recombinant factor VIII compared with a monoclonally purified concentrate (Hemofil M®)
100. Development and small-scale production of a severely heated factor VIII concentrate
101. A general expression for coupled enzyme assays of hysteretic enzymes
102. Lagtime, a program for calculating coupled enzyme assay parameters
103. Kinetics of coupled enzyme reactions
104. A continuous spectrophotometric method for the determination of glycogen phosphorylase-catalyzed reaction in the direction of glycogen synthesis
105. Discrepancies in potency assessment of recombinant FVIII concentrates
106. Novel forms of B-domain-deleted recombinant factor VIII molecules. Construction and biochemical characterization
107. Recombinant factor VIII SQ - inactivation kinetics in aqueous solution and the influence of disaccharides and sugar alcohols
108. Development of freeze-dried albumin-free formulation of recombinant factor VIII SQ
109. In vivo recovery with products of very high purity - assay discrepancies
110. Influence of phospholipids on the assessment of factor VIII activity
111. Biochemical, immunological, and in vivo functional characterization of B-domain deleted factor VIII
112. Biological activity of recombinant factor VIII variants lacking the central B-domain and the heavy-chain sequence Lys713-Arg740: Discordant in vitro and in vivo activity